Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision
Not Applicable
Completed
- Conditions
- Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity
- Interventions
- Procedure: intravitreal injection
- Registration Number
- NCT01053858
- Lead Sponsor
- Hallym University Medical Center
- Brief Summary
To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion
Exclusion Criteria
- previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
- Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
- neovascularization on the disc or elsewhere or rubeosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description bevacizumab intravitreal injection intravitreal bevacizumab or triamcinolone determined by single physician triamcinolone intravitreal injection -
- Primary Outcome Measures
Name Time Method best corrected visual acuity baseline, 1 month, 2 months, 3 months, 6 months, 12 months
- Secondary Outcome Measures
Name Time Method central macular thickness by optical coherence tomography baseline, 1 month, 2 months, 3 months, 6 months 12months
Trial Locations
- Locations (1)
keoung ik Na
🇰🇷Chuncheon, Anyang, Korea, Republic of